Tvardi Therapeutics (NASDAQ:TVRD) Given “Buy” Rating at BTIG Research

Tvardi Therapeutics (NASDAQ:TVRD)‘s stock had its “buy” rating restated by analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They currently have a $15.00 target price on the stock. BTIG Research’s target price suggests a potential upside of 422.10% from the stock’s previous close.

A number of other analysts have also issued reports on TVRD. Wall Street Zen lowered shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. HC Wainwright assumed coverage on shares of Tvardi Therapeutics in a research note on Monday, June 8th. They issued a “buy” rating and a $9.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.80.

Tvardi Therapeutics Trading Up 42.9%

Shares of TVRD traded up $0.86 during midday trading on Tuesday, reaching $2.87. 53,991,611 shares of the company were exchanged, compared to its average volume of 503,905. The stock has a 50-day moving average price of $3.05 and a 200-day moving average price of $3.53. The company has a market cap of $26.95 million, a price-to-earnings ratio of -0.91 and a beta of 0.39. Tvardi Therapeutics has a 1-year low of $1.50 and a 1-year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.08). Equities research analysts anticipate that Tvardi Therapeutics will post -2.39 earnings per share for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Tvardi Therapeutics by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock worth $16,335,000 after purchasing an additional 20,757 shares during the last quarter. American Financial Group Inc. bought a new position in Tvardi Therapeutics during the 4th quarter worth $962,000. Vestal Point Capital LP acquired a new stake in Tvardi Therapeutics in the third quarter worth $6,508,000. Geode Capital Management LLC increased its position in Tvardi Therapeutics by 6.2% in the fourth quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock worth $676,000 after buying an additional 9,214 shares during the period. Finally, State Street Corp lifted its stake in Tvardi Therapeutics by 83.7% in the fourth quarter. State Street Corp now owns 115,501 shares of the company’s stock valued at $497,000 after buying an additional 52,637 shares during the last quarter. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.